In brief: Takeda shareholders back Shire acquisition

Pfizer boosts oncology presence with $11.4bn Array BioPharma buy
Credit: pichetw

Takeda Pharmaceutical has gained the backing of its shareholders for its proposed £46 billion acquisition or Ireland’s Shire.

“We are delighted that our shareholders have given their strong support to our acquisition of Shire,” said Christophe Weber, President and CEO of Takeda.

“With shareholder approval secured, we are looking forward to closing the acquisition in the coming weeks to create a more competitive, agile, highly profitable, and therefore more resilient company, poised to deliver highly innovative medicines and transformative care to patients around the world.”

With this approval, the acquisition is now expected to complete on January 8 2019.